Price
$0.4176
Increased by +3.11%
Dollar Volume (20D)
69.24 K
ADR%
7.4
Earnings Report Date (estimate)
Mar 29, 24
Shares Float
44.6 M
Shares Outstanding
48.84 M
Shares Short
383.34 K
Market Cap.
20.4 M
Beta
-0.14
Price / Earnings
N/A
20D Range
0.38 0.46
50D Range
0.38 0.54
200D Range
0.38 0.75
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 15, 23 -0.16
Decreased by -23.08%
-0.11
Decreased by -45.45%
Aug 15, 23 -0.1
Increased by 0%
-0.11
Increased by +9.09%
May 15, 23 -0.08
Increased by 0%
-0.11
Increased by +27.27%
Mar 16, 23 -0.09
Increased by +25%
-0.12
Increased by +25%
Nov 15, 22 -0.13
Decreased by -62.5%
-0.08
Decreased by -62.5%
Aug 15, 22 -0.1
Increased by +16.67%
-0.07
Decreased by -42.86%
May 13, 22 -0.08
Increased by 0%
-0.07
Decreased by -14.29%
Mar 31, 22 -0.12
Decreased by -33.33%
-0.08
Decreased by -50%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Oct 31, 23 46 K
Increased by +119.05%
-7.82 M
Decreased by -25.08%
Decreased by -16.99 K%
Increased by +42.9%
Jul 31, 23 42 K
Increased by +40%
-4.91 M
Increased by +1.96%
Decreased by -11.69 K%
Increased by +29.97%
Apr 30, 23 49 K
Increased by +48.48%
-2.85 M
Increased by +36.56%
Decreased by -5.81 K%
Increased by +57.28%
Jan 31, 23 56 K
Increased by +12%
-4.3 M
Increased by +26.51%
Decreased by -7.67 K%
Increased by +34.39%
Oct 31, 22 21 K
Decreased by -36.36%
-6.25 M
Decreased by -63.33%
Decreased by -29.76 K%
Decreased by -156.66%
Jul 31, 22 30 K
Increased by +30.43%
-5.01 M
Increased by +14.79%
Decreased by -16.69 K%
Increased by +34.67%
Apr 30, 22 33 K
Increased by +17.86%
-4.49 M
Decreased by -25.4%
Decreased by -13.6 K%
Decreased by -6.4%
Jan 31, 22 50 K
Increased by +19.05%
-5.85 M
Decreased by -48.6%
Decreased by -11.69 K%
Decreased by -24.83%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.